Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer.
Malinda T WestShaun M GoodyearEvthokia A HobbsAndy KaempfThomas KartikaJessica RibkoffBrie ChunZahi I MitriPublished in: The oncologist (2023)
This study highlights post-CDKi outcomes and the need for further molecular characterization and novel therapies to improve treatments for patients with HR+/HER2- MBC.